IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources, extensive domain expertise and network of partners. IQVIA Connected Intelligence delivers actionable insights and powerful solutions with speed and agility, enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, the company conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. The company's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

• Employees: 87,000 (approximately)
• Geographic Footprint: More than 100 countries
• Headquarters: Durham, North Carolina
• Founded: Not explicitly stated in filing
• Number of locations/facilities: 291 offices and laboratories (approximately)

• CEO: Ari Bousbib
• CFO: Ronald E. Bruehlman
• President, Research & Development Solutions: W. Richard Staub, III
• President, Corporate Strategy and Enterprise Networks: Kevin C. Knightly
• Executive Vice President, General Counsel and Secretary: Eric Sherbet

• Annual Revenue: $14.984 billion (FY2023)
• Net Income: $1.358 billion (FY2023)
• Total Assets: $26.681 billion (as of December 31, 2023)
• Key Financial Highlights: The company experienced strong demand and operational results for its Research & Development Solutions offerings. The company also experienced growth in certain Technology & Analytics Solutions offerings, such as multi-channel marketing and real world solutions. The company's targeted productivity initiatives contributed to overall net income and earnings per share growth, and the company ended the year with its highest ever remaining performance obligations of approximately $31.7 billion as of December 31, 2023.

IQVIA offers hundreds of distinct services, applications, technology platforms and solutions to help its clients make critical decisions and perform better. The company has three reportable segments:

• Technology & Analytics Solutions: Provides mission critical information, technology solutions and real world insights and services.
• Research & Development Solutions: Provides outsourced clinical research and clinical trial services.
• Contract Sales & Medical Solutions: Provides health care provider (including contract sales) and patient engagement services.

These offerings complement each other and can provide enhanced value to the company's clients when delivered together, with each driving demand for the other.

• Technology & Analytics Solutions: $5.862 billion in revenues (FY2023)
• Research & Development Solutions: $8.395 billion in revenues (FY2023)
• Contract Sales & Medical Solutions: $727 million in revenues (FY2023)

IQVIA's strategy for achieving growth includes:

• Continuing to innovate through IQVIA Connected Intelligence by leveraging its information, advanced analytics, transformative technology and significant domain expertise.
• Building upon its extensive client relationships and leveraging its global presence.
• Expanding the penetration of its offerings to the broader healthcare marketplace.
• Expanding its portfolio through strategic acquisitions.

IQVIA competes in a market of greater than $330 billion consisting of outsourced research and development, real-world evidence and connected health and technology enabled clinical and commercial operations markets for life sciences companies and the broader healthcare industry.

• Key Competitors: Accenture, Aetion, Panalgo, Cognizant Technology Solutions, Fortrea, Deloitte, Pharmaceutical Product Development, Inc., Relx, IBM, Infosys, Cerner, McKinsey, NielsenIQ, Optum Insight, Parexel International Corporation, Press Ganey, RTI Health Solutions, ICON plc, Definitive Healthcare, Cegedim, Tempus, Merative, CompuGroup Medical, Medidata, Clarivate, Veeva, and ZS Associates.
• Industry Trends: Growth and innovation in the life sciences industry, increased complexity in research and development, financial pressures driving the need for increased efficiency, evolving need to integrate and structure expanding sources of data, and need for demonstrated value in healthcare.

• Risks Relating to Our Business: The potential loss or delay of contracts, underpricing contracts, failure to meet productivity objectives, inability to develop and market new services or enter new markets, inability to identify, acquire and integrate existing businesses, and inability to attract suitable investigators and patients for clinical trials.
• Intellectual Property Risks: Dependence on third parties for data and support services, inability to protect intellectual property rights, claims of infringement by others, and reliance on licenses from third parties.
• IT Systems and Information Risks: Security breaches and unauthorized use of IT systems, challenges with technology acquisition, development and deployment, and data protection and privacy law compliance.
• Client Risks: Consolidation in client industries, client or therapeutic concentration, relationships with competing clients, and the risk of clients being unable to fund the completion of clinical trials.